90Y-hPAM4

BIOLOGICAL2 trials

Sponsors

Gilead Sciences

Conditions

Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic CancerPancreatic Cancer

Phase 1

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

CompletedNCT00597129

Gilead SciencesPancreatic Cancer

Start: 2004-08-31End: 2007-10-31Updated: 2021-08-19

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

WithdrawnNCT01510561

Gilead SciencesMetastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Pancreatic Cancer

Start: 2012-03-31End: 2015-09-30Updated: 2021-08-19

Related Papers

Feasibility and results of a randomized phase Ιb study of fractionated <sup>90</sup>Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.

Journal of Clinical Oncology2014-05-208 citations